M.D.

Dr. James Douketis is the Director of the Vascular Medicine Program and Staff Physician in Vascular Medicine and General Internal Medicine at St. Joseph’s Healthcare Hamilton. He is a Professor in the Department of Medicine at McMaster University and the Associate Director of the Clinical Teaching Unit at St. Joseph’s Healthcare. He received his Doctor of Medicine degree and completed his residency in Internal Medicine at the University of Toronto. He then completed a fellowship in thromboembolic disease at McMaster University.  
Dr. Douketis’ research interests include perioperative antithrombotic therapy, prognosis of patients with venous thromboembolism, bleeding risks during antithrombotic therapy, hormonal therapy and thrombosis, prevention of venous thromboembolism in medical patients, and clinical practice guideline development for the prevention and treatment of obesity.

Dr. Douketis is the Deputy Editor of ACP Journal Club and has 175 scientific publications, of which over 125 are peer-reviewed articles.

Dr. Douketis lives in Hamilton with his wife, Dr. Margaret Nowaczyk, a clinical geneticist, and two boys, Jack and Luke, and is a cellist with Symphony Hamilton.

Email:  jdouket@mcmaster.ca

Educational Activities

   * Associate Director, Clinical Teaching Unit at St. Joseph’s Healthcare

   * Current Graduate Student HRM Program: Erin Jamula

Community Activities

   * Vice-President, Symphony Hamilton

   * Cellist, Symphony Hamilton and Masterworks of Oakville

Selected Publications

Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. The risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-62.

Douketis JD, Feightner JW, Attia J, Feldman WF, with the Canadian Task Force on Preventive Health Care. Periodic health examination, 1999 update: Detection prevention and treatment of obesity. CMAJ 1999;160:513-24.

Linkins L, Choi P, Douketis JD. What is the clinical impact of bleeding in patients with venous thromboembolism who are receiving oral anticoagulant therapy? An assessment of case-fatality and risk of major bleeding. Ann Intern Med 2003;139:893-900.

Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation in patients who require temporary interruption of warfarin for an elective surgical or invasive procedure: assessment of a standardized peri-procedural anticoagulation regimen. Arch Intern Med 2004;169:1319-26.

Douketis JD, Julian JA, Kearon C,Anderson DR, Crowther MA, Bates SM, et al.  Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005;5:943-8.

Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E.2006  Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:S1-13.

Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P.  The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007;147:138-45.

Douketis JD, Berger PH, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):299S-339S.

Johnson SA, Stevens SM, Woller SC, Lake E, Donadini M, Cheng J, Labarere J, Douketis J. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 2010;303:438-45.

Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010;153:523-31.

‍